Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $300 from $294 at Baird
- Wolfe starts Biogen at Peer Perform, sees limited downside risk
- Biogen initiated with a Peer Perform at Wolfe Research
- Raymond James sees EU Leqembi uptake as more modest for Biogen than in U.S.
- Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease